{"id":"NCT01001988","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers","officialTitle":"Long-term Follow-up of Immunogenicity of a Single Dose of JE-CV in Toddlers in Thailand and the Philippines","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08-07","primaryCompletion":"2013-10-16","completion":"2013-10-16","firstPosted":"2009-10-27","resultsPosted":"2017-11-29","lastUpdate":"2017-11-29"},"enrollment":596,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Encephalitis","Japanese Encephalitis"],"interventions":[{"type":"OTHER","name":"Blood sample","otherNames":[]},{"type":"BIOLOGICAL","name":"JE-CV administered in Study JEC02","otherNames":[]}],"arms":[{"label":"Study group","type":"EXPERIMENTAL"}],"summary":"This is a long-term follow-up of the persistence of immune response in participants who previously received a single dose of JE-CV at age 12 to 18 months in Study JEC02 (NCT00735644) . No vaccination was administered during the present long-term follow-up study.\n\nPrimary Objective:\n\n* To describe the yearly persistence of humoral immune response to Japanese encephalitis after a single dose of JE-CV","primaryOutcome":{"measure":"Percentage of Participants With Japanese Encephalitis Seroprotection Following a Single Dose of JE-CV","timeFrame":"Day 0 (pre-vaccination) from study JEC02, Day 28 post-vaccination from study JEC02, and at Years 1, 2, 3, 4, and 5 post-vaccination","effectByArm":[{"arm":"Study Group","deltaMin":2.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":4,"countries":["Philippines","Thailand"]},"refs":{"pmids":[],"seeAlso":["http://www.sanofipasteur.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":591},"commonTop":[]}}